Danielle Brill
Stock Analyst at Truist Securities
(3.45)
# 945
Out of 5,008 analysts
84
Total ratings
39.73%
Success rate
8.78%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $56 → $80 | $70.72 | +13.12% | 2 | Oct 2, 2025 | |
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $410.28 | - | 3 | Sep 3, 2025 | |
| IRON Disc Medicine | Initiates: Buy | $86 | $67.89 | +26.68% | 6 | Jul 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Buy | $385 | $459.58 | -16.23% | 1 | Jul 21, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $27.05 | +77.45% | 8 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Buy | $64 | $14.91 | +329.24% | 2 | Jul 21, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $163 | $137.00 | +18.98% | 6 | Jul 21, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $66 | $54.22 | +21.73% | 1 | Jul 21, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | $30 | $23.12 | +29.76% | 1 | Jul 21, 2025 | |
| JCAP Jefferson Capital | Initiates: Buy | $24 | $18.06 | +32.89% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $57.92 | -10.22% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $14.90 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $54.70 | +44.42% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $10.51 | +71.27% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $36 | $16.11 | +123.46% | 4 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $23.12 | +548.79% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $152.21 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $797.35 | -24.12% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $21.54 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $39.16 | +27.68% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $40.87 | +24.79% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $7.95 | +1,157.86% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $63.91 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.07 | - | 5 | Jun 27, 2023 |
Palvella Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $56 → $80
Current: $70.72
Upside: +13.12%
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $410.28
Upside: -
Disc Medicine
Jul 21, 2025
Initiates: Buy
Price Target: $86
Current: $67.89
Upside: +26.68%
Alnylam Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $385
Current: $459.58
Upside: -16.23%
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $27.05
Upside: +77.45%
Tectonic Therapeutic
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $14.91
Upside: +329.24%
Neurocrine Biosciences
Jul 21, 2025
Initiates: Buy
Price Target: $163
Current: $137.00
Upside: +18.98%
BridgeBio Pharma
Jul 21, 2025
Initiates: Buy
Price Target: $66
Current: $54.22
Upside: +21.73%
Centessa Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $23.12
Upside: +29.76%
Jefferson Capital
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $18.06
Upside: +32.89%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $57.92
Upside: -10.22%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.90
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $54.70
Upside: +44.42%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $10.51
Upside: +71.27%
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $16.11
Upside: +123.46%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $23.12
Upside: +548.79%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $152.21
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $797.35
Upside: -24.12%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $21.54
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $39.16
Upside: +27.68%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $40.87
Upside: +24.79%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $7.95
Upside: +1,157.86%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $63.91
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.07
Upside: -